Skip to content
Korsuva, Kapruvia(difelikefalin)
Kapruvia, Korsuva (difelikefalin) is a protein pharmaceutical. Difelikefalin was first approved as Korsuva on 2021-08-23. It is used to treat pruritus in the USA. It has been approved in Europe to treat pruritus. The pharmaceutical is active against kappa-type opioid receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Korsuva
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Difelikefalin acetate
Tradename
Company
Number
Date
Products
KORSUVACara TherapeuticsN-214916 RX2021-08-23
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
korsuvaNew Drug Application2021-12-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
pruritusHP_0000989D011537L29
Agency Specific
FDA
EMA
Expiration
Code
DIFELIKEFALIN ACETATE, KORSUVA, CARA THERAP
2026-08-23NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Difelikefalin Acetate, Korsuva, Cara Therap
74025642027-11-12DS, DPU-3204
77139372027-11-12DS, DPU-3204
77279632027-11-12DS, DPU-3204
82170072027-11-12U-3204
82367662027-11-12U-3204
84868942027-11-12U-3204
85361312027-11-12DS, DPU-3204
93343052027-11-12U-3204
93593992027-11-12U-3204
100175362027-11-12DPU-3204
101382702027-11-12U-3204
107935962027-11-12DS, DPU-3204
ATC Codes
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AX: Other therapeutic products in atc
— V03AX04: Difelikefalin
HCPCS
No data
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PruritusD011537HP_0000989L29—43——7
Chronic renal insufficiencyD051436N18—12——3
Atopic dermatitisD003876EFO_0000274L20—11——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acute painD059787R52—2———2
Knee osteoarthritisD020370EFO_0004616M17—1———1
Hip osteoarthritisD015207EFO_1000786M16—1———1
ArthritisD001168EFO_0005856M05-M14—1———1
Rheumatic diseasesD012216M79.0—1———1
Joint diseasesD007592HP_0003040M12.9—1———1
Musculoskeletal diseasesD009140—1———1
OsteoarthritisD010003EFO_0002506M15-M19—1———1
Postoperative painD010149G89.18—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—2————2
Renal dialysisD006435EFO_0010690Z99.22————2
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDIFELIKEFALIN
INNdifelikefalin
Description
Difelikefalin, sold under the brand name Korsuva, is an analgesic opioid peptide used for the treatment of moderate to severe itching. It acts as a peripherally specific, highly selective agonist of the κ-opioid receptor (KOR).
Classification
Protein
Drug classenkephalin agonists (various indications)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(C(=O)O)CC1
Identifiers
PDB—
CAS-ID1024828-77-0
RxCUI—
ChEMBL IDCHEMBL3989915
ChEBI ID—
PubChem CID24794466
DrugBankDB11938
UNII IDNA1U919MRO (ChemIDplus, GSRS)
Target
Agency Approved
OPRK1
OPRK1
Organism
Homo sapiens
Gene name
OPRK1
Gene synonyms
OPRK
NCBI Gene ID
4986
Protein name
kappa-type opioid receptor
Protein synonyms
kappa opioid receptor, Opiate receptor, kappa-1
Uniprot ID
Q499G4
Mouse ortholog
Oprk1 (18387)
kappa-type opioid receptor (P33534)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 120 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details